TY - JOUR
T1 - The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients
T2 - A secondary analysis of a randomized controlled trial
AU - Fotso Soh, Jocelyn
AU - Almadani, Ahmad
AU - Beaulieu, Serge
AU - Rajji, Tarek
AU - Mulsant, Benoit H
AU - Su, Chien-Lin
AU - Renaud, Suzane
AU - Mucsi, Istvan
AU - Torres-Platas, S Gabriela
AU - Levinson, Andrea
AU - Schaffer, Ayal
AU - Dols, Annemiek
AU - Cervantes, Pablo
AU - Low, Nancy
AU - Herrmann, Nathan
AU - Mantere, Outi
AU - Rej, Soham
N1 - Copyright © 2019 Elsevier B.V. All rights reserved.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - OBJECTIVES: Statins have recently been linked to having effects on cognition and mood in mood disorders, though results are mixed. In this paper, we use data from a recent randomized controlled trial (RCT) to examine the effect of statins on cognition and mood in patients with Bipolar Disorder (BD) and Major Depressive Disorder (MDD).METHODS: This is a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial (n = 60) originally designed to examine the effect of atorvastatin (n = 27) versus placebo (n = 33) for lithium-induced diabetes insipidus in BD and MDD patients who were using lithium. For this analysis, the primary outcome was global cognition Z-score at 12-weeks adjusted for baseline. The secondary cognition outcomes were (1) Screen for Cognitive Impairment in Psychiatry (SCIP), and (2) executive function Z-score. The primary mood outcome (secondary outcome of this analysis) was depression relapse during 12-week follow-up (Mongomery Asberg Depression Rating Scale (MADRS) ≥10). The secondary mood outcomes were (1) relapse rate into a manic episode, and (2) relapse rate into any mood episode.RESULTS: After 12 weeks follow-up, atorvastatin and placebo groups did not differ in terms of global cognition Z-score (β = -0.009287 (-0.1698,0.1512), p-value = 0.91). Similarly, composite Z-scores for SCIP and executive functions did not differ significantly. Depression relapse during 12-week follow-up was not significantly different between the groups (χ2 (1) = 0.148, p-value = 0.70). Similarly, there was no difference between groups regarding relapse into mania.CONCLUSION: In BD and MDD patients with lithium-induced nephrogenic diabetes insipidus randomized to atorvastatin or placebo, we found no significant differences in cognition and mood outcomes at 12-week follow-up.
AB - OBJECTIVES: Statins have recently been linked to having effects on cognition and mood in mood disorders, though results are mixed. In this paper, we use data from a recent randomized controlled trial (RCT) to examine the effect of statins on cognition and mood in patients with Bipolar Disorder (BD) and Major Depressive Disorder (MDD).METHODS: This is a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial (n = 60) originally designed to examine the effect of atorvastatin (n = 27) versus placebo (n = 33) for lithium-induced diabetes insipidus in BD and MDD patients who were using lithium. For this analysis, the primary outcome was global cognition Z-score at 12-weeks adjusted for baseline. The secondary cognition outcomes were (1) Screen for Cognitive Impairment in Psychiatry (SCIP), and (2) executive function Z-score. The primary mood outcome (secondary outcome of this analysis) was depression relapse during 12-week follow-up (Mongomery Asberg Depression Rating Scale (MADRS) ≥10). The secondary mood outcomes were (1) relapse rate into a manic episode, and (2) relapse rate into any mood episode.RESULTS: After 12 weeks follow-up, atorvastatin and placebo groups did not differ in terms of global cognition Z-score (β = -0.009287 (-0.1698,0.1512), p-value = 0.91). Similarly, composite Z-scores for SCIP and executive functions did not differ significantly. Depression relapse during 12-week follow-up was not significantly different between the groups (χ2 (1) = 0.148, p-value = 0.70). Similarly, there was no difference between groups regarding relapse into mania.CONCLUSION: In BD and MDD patients with lithium-induced nephrogenic diabetes insipidus randomized to atorvastatin or placebo, we found no significant differences in cognition and mood outcomes at 12-week follow-up.
KW - Bipolar disorder
KW - Cognition
KW - Major depressive disorder
KW - Placebo
KW - Randomized clinical trial
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85074757765&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jad.2019.11.013
DO - https://doi.org/10.1016/j.jad.2019.11.013
M3 - Article
C2 - 31733459
SN - 0165-0327
VL - 262
SP - 149
EP - 154
JO - Journal of affective disorders
JF - Journal of affective disorders
ER -